Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ocugen Inc (OCGN)
NASDAQ:OCGN
OCGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.64 - $2.11
Previous CloseN/A
Volume1.89M
Average Volume (3M)3.98M
Market Cap
$212.10M
Enterprise Value$244.09M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Mar 28, 2025EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding290,946,930
10 Day Avg. Volume3,807,750
30 Day Avg. Volume3,978,720
Standard Deviation0.96
R-Squared0.04
Alpha0.11
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)22.77
Price to Cash Flow (P/CF)-4.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit45.78
Enterprise Value/Ebitda-5.09
Forecast
1Y Price Target
$6.67Price Target Upside852.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressOcugen announced the completion of dosing in the Phase 2 portion of the P1/2 ArMaDa study for OCU410 in geographic atrophy.
Efficacy Results9-month data from the P1 portion of the study showed both a slowing of lesion growth with a magnitude exceeding the approved complement inhibitors and improvements in visual acuity.
Safety ProfilePositive safety and tolerability profile with no serious adverse events related to OCU410.
Bears Say
Development TimelineOCU410 is still in a Phase 2 trial, and a Phase 3 study is planned, indicating a long path to potential market approval.
Funding ConcernsManagement plans to design a Phase 3 pivotal study based on the results from the Phase 2 during 2026, pending the availability of funds.
Market CompetitionOCU410's success is contingent on sustaining superior efficacy in larger studies compared to approved therapies.
---
Ownership Overview
1.16% Insiders
8.16% Mutual Funds
1.06% Other Institutional Investors
79.84% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OCGN FAQ
What was Ocugen Inc’s price range in the past 12 months?
Ocugen Inc lowest stock price was $0.64 and its highest was $2.10 in the past 12 months.
What is Ocugen Inc’s market cap?
Ocugen Inc’s market cap is $212.10M.
When is Ocugen Inc’s upcoming earnings report date?
Ocugen Inc’s upcoming earnings report date is Mar 28, 2025 which is in 35 days.
How were Ocugen Inc’s earnings last quarter?
Ocugen Inc released its earnings results on Nov 08, 2024. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.055 by $0.005.
Is Ocugen Inc overvalued?
According to Wall Street analysts Ocugen Inc’s price is currently Undervalued.
Does Ocugen Inc pay dividends?
Ocugen Inc does not currently pay dividends.
What is Ocugen Inc’s EPS estimate?
Ocugen Inc’s EPS estimate is -0.05.
How many shares outstanding does Ocugen Inc have?
Ocugen Inc has 290,946,930 shares outstanding.
What happened to Ocugen Inc’s price movement after its last earnings report?
Ocugen Inc reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.055. Following the earnings report the stock price went down -8.333%.
Which hedge fund is a major shareholder of Ocugen Inc?
Currently, no hedge funds are holding shares in OCGN
---
Ocugen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.67 (852.86% Upside)
$6.67 (852.86% Upside)
Blogger Sentiment
Bullish
OCGN Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $31.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days >0.1%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.76%
12-Months-Change
Fundamentals
Return on Equity
-103.30%
Trailing 12-Months
Asset Growth
-17.07%
Trailing 12-Months
Company Description
Ocugen Inc
Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline of therapies includes OCU400, OCU410, OCU200, OCU100, and OCU300. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA.
---
OCGN Company Deck
---
OCGN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant clinical and regulatory advancements, successful financing, and positive safety profiles for Ocugen's gene therapy programs. Despite stable operating expenses and cash position, the strategic achievements suggest confidence in Ocugen's future potential.Read More>---
OCGN Stock 12 Month Forecast
Average Price Target
$6.67
▲(852.86% Upside)
Technical Analysis
Organovo Holdings
―
Fate Therapeutics
―
ADMA Biologics
―
Editas Medicine
―
Crispr Therapeutics AG
―
Best Analysts Covering OCGN
1 Year
1 Year Success Rate
6/17 ratings generated profit
1 Year Average Return
+18.56%
reiterated a buy rating 8 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 35.29% of your transactions generating a profit, with an average return of +18.56% per trade.
---